Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969124 | 0.82 | KCNQ2 (0.33) | KCNQ2LIPE | |
| SCHEMBL22502088 | 0.80 | LMNA (0.36) | KCNQ2 | |
| SCHEMBL2804738 | 0.77 | KCNQ2 (0.34) | KCNQ2 | |
| SCHEMBL141779 | 0.75 | LMNA (0.34) | KCNQ2 | |
| SCHEMBL22045060 | 0.75 | HSD11B1 (0.34) | — | |
| SCHEMBL1973881 | 0.75 | DGAT1 (0.36) | KCNQ2 | |
| SCHEMBL13052071 | 0.73 | HSD11B1 (0.37) | — | |
| SCHEMBL4321314 | 0.72 | MEN1 (0.33) | LIPE | |
| SCHEMBL2803172 | 0.72 | MAPT (0.38) | KCNQ2 | |
| SCHEMBL21169218 | 0.70 | CYP1A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | KCNQ2 2211/4885LIPE 188/4885 |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | PLA2G4A, PLA2G1B, PLA2G4B | KCNQ2 2844/4885LIPE 71/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | KCNQ2 2381/4885LIPE 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.